Neurogram

Neurogram operates at the intersection of neurotechnology, digital health, diagnostics, and clinical software. Its stated focus is EEG workflow infrastructure: bringing signal acquisition, review, analysis, and reporting together while supporting different EEG equipment. Neurogram reports that its platform is ANVISA-approved and used across Brazil, and its website cites more than 60,000 processed EEG hours and adoption by 12% of Brazilian neurophysiologists. These are company-level adoption claims rather than a complete market-share assessment. The product range also includes Neurovital, described as a real-time monitoring solution for intensive care units, extending the company’s scope beyond EEG review and reporting. With a Seed-stage funding profile and no disclosed valuation, Neurogram appears to be an early-stage specialist rather than a broadly scaled medical-device incumbent.

Neurogram’s timeline shows a progression from early financing to a larger Seed round. Founded in 2021, the company raised a $1.4 million Pre-seed round on Jan 1, 2022, led by Starship Ventures. The next clear financing inflection point came on Jul 31, 2025, when Neurogram announced a $3 million Seed round led by Headline, with Hustle Fund also participating. Total funding is listed as $4.4 million across three rounds. A growth signal indicates that the company entered an expansion phase in 2025 following financing, but no hiring roles, headcount changes, or later funding milestones are specified. Product development provides another indication of direction: the EEG Platform combines collection through reporting, while Neurovital is described as a planned real-time ICU monitoring solution. Overall, the evidence points to continued product development and expansion after the 2025 round, but does not establish the pace of revenue growth or subsequent commercial adoption.